0001562180-23-006088.txt : 20230801 0001562180-23-006088.hdr.sgml : 20230801 20230801163524 ACCESSION NUMBER: 0001562180-23-006088 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230731 FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Snow Ellen CENTRAL INDEX KEY: 0001786643 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 231132301 MAIL ADDRESS: STREET 1: C/O PEAR THERAPEUTICS, INC. STREET 2: 200 STATE STREET, 13TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2023-07-31 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001786643 Snow Ellen C/O AKEBIA THERAPEUTICS, INC 245 FIRST ST. CAMBRIDGE MA 02142 false true false false SVP, CFO and Treasurer false Common Stock 2023-07-31 4 A false 370000.00 0.00 A 370000.00 D Stock Option (Right to buy) 1.67 2023-07-31 4 A false 560000.00 0.00 A 2033-07-31 Common Stock 560000.00 560000.00 D The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the RSUs will vest upon each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer. The options were granted by the Issuer as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer. /s/Carolyn Rucci, attorney-in-fact for Ellen Snow 2023-08-01